Syros Pharmaceuticals announced that its phase 3 trial of tamibarotene in combination with azacitidine did not meet the primary endpoint for the treatment of myelodysplastic syndrome.

In the univariate analysis, those on an SGLT-2i/GLP-1 RA had a reduced risk for mortality, incident MI, and composite. (HealthDay News) — For patients with ischemic stroke, sodium-glucose ...

(HealthDay News) — Virtual yoga classes may be a feasible, safe, and effective treatment option for chronic low back pain (CLBP), according to a study published online Nov. 1 in JAMA Network Open.

Spreading medical misinformation to the public and providing misinformation to patients receiving treatment were among the least common reasons for discipline. A large study suggests that, across the ...

The sNDA was submitted to support full approval of OCA for this indication based on data from the COBALT trial, as well as real-world evidence.